Clinical Trial Update: ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS) [Phase 4]

View source ↗

Summary

Phase 4 trial ASTERIAS comparing aspirin versus triflusal for reducing vascular events in patients with atherothrombosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherothrombosis

Drugs mentioned

• Aspirin (Aspirin)
• Triflusal (triflusal)

Snippet

Sponsor: University of Ioannina | Conditions: Atherothrombosis | Phase 4 | Status: COMPLETED